Business Description
Spexis AG
ISIN : CH0106213793
Share Class Description:
PPHOF: Registered SharesCompare
Compare
Traded in other countries / regions
SPEX.Switzerland29Y.GermanySPEXz.UKPPHOF.USA IPO Date
2019-10-29Description
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.64 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -55.7 | |||||
| 3-Year EPS without NRI Growth Rate | -38.1 | |||||
| 3-Year FCF Growth Rate | -17.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | |||||
| Quick Ratio | 0.38 | |||||
| Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -73.9 | |||||
| Shareholder Yield % | -46.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -151.03 | |||||
| ROA % | -77.04 | |||||
| ROIC % | -79.3 | |||||
| ROC (Joel Greenblatt) % | -1603.23 | |||||
| ROCE % | -100.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.28 | |||||
| EV-to-EBIT | -0.6 | |||||
| EV-to-EBITDA | -0.63 | |||||
| EV-to-FCF | -2.06 | |||||
| Earnings Yield (Greenblatt) % | -166.67 | |||||
| FCF Yield % | -161.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PPHOF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spexis AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 2.5 - 2.5 | ||
| Shares Outstanding (Mil) | 52.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spexis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spexis AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spexis AG Frequently Asked Questions
What is Spexis AG(PPHOF)'s stock price today?
The current price of PPHOF is $2.50. The 52 week high of PPHOF is $2.50 and 52 week low is $2.50.
When is next earnings date of Spexis AG(PPHOF)?
The next earnings date of Spexis AG(PPHOF) is .
Does Spexis AG(PPHOF) pay dividends? If so, how much?
Spexis AG(PPHOF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers